BUY NOW For Sale 70%!
buy viagra

Linola akut beipackzettel ciprofloxacin

Logo of cmaj

CMAJ. 1994 Mar 1; 150(5): 669–676.

PMCID: PMC1486352

T J Louie


OBJECTIVE: To optimize the use of ciprofloxacin, a synthetic fluoroquinolone, in community and hospital practice, and to minimize overprescribing by providing an overview of the literature and recommendations for appropriate use. OPTIONS: First-line treatment for infections in which ciprofloxacin is shown to be effective, treatment with oral ciprofloxacin rather than parenteral therapy with another drug, and step-down therapy with oral ciprofloxacin after initial parenteral treatment. OUTCOMES: In order of importance: efficacy, side effects and cost. EVIDENCE: A MEDLINE search of articles concerning ciprofloxacin, including in-vitro and pharmacokinetic studies using recognized standard methods with appropriate controls and published in recognized peer-reviewed journals, and randomized, controlled, double-blind clinical trials. VALUES: The Committee on Antimicrobial Agents of the Canadian Infectious Disease Society (CIDS) and a recognized expert (T.J.L.) recommended use of ciprofloxacin to treat infections against which it has proved effective both in vitro and in randomized controlled trials. They took into account its value as an oral replacement for other drugs given parenterally and development of resistance. BENEFITS, HARMS AND COSTS: With more appropriate use of ciprofloxacin there will be less development of resistant pathogens. For certain infections patients who would otherwise require admission to hospital could be treated at home and patients initially admitted for parenteral therapy could be discharged sooner on oral therapy with ciprofloxacin. RECOMMENDATIONS: Ciprofloxacin may be considered as first-line treatment for a number of infections in which gram-negative pathogens are proven or strongly suspected, including complicated urinary tract infections, bacterial prostatitis, bacterial diarrhea, selected bone and joint infections, malignant otitis externa, bronchopulmonary infections in patients with cystic fibrosis and selected pneumonia cases. VALIDATION: The paper was prepared, reviewed and revised by the Committee on Antimicrobial Agents of the CIDS. It was then reviewed and revised further by the Council of the CIDS. SPONSOR: The CIDS is solely responsible for developing, funding and endorsing these guidelines.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.7M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.


icon of scanned page 669


icon of scanned page 670


icon of scanned page 671


icon of scanned page 672


icon of scanned page 673


icon of scanned page 674


icon of scanned page 675


icon of scanned page 676



Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Neu HC. Ciprofloxacin: an overview and prospective appraisal. Am J Med. 1987 Apr 27;82(4A):395–404. [PubMed]
  • Shen LL, Pernet AG. Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: the target of the drugs is DNA. Proc Natl Acad Sci U S A. 1985 Jan;82(2):307–311. [PMC free article] [PubMed]
  • Sanders CC, Sanders WE, Jr, Goering RV. Overview of preclinical studies with ciprofloxacin. Am J Med. 1987 Apr 27;82(4A):2–11. [PubMed]
  • Bellido F, Pechère JC. Laboratory survey of fluoroquinolone activity. Rev Infect Dis. 1989 Jul-Aug;11 (Suppl 5):S917–S924. [PubMed]
  • Saito A, Koga H, Shigeno H, Watanabe K, Mori K, Kohno S, Shigeno Y, Suzuyama Y, Yamaguchi K, Hirota M, et al. The antimicrobial activity of ciprofloxacin against Legionella species and the treatment of experimental Legionella pneumonia in guinea pigs. J Antimicrob Chemother. 1986 Aug;18(2):251–260. [PubMed]
  • Barry AL, Jones RN. In vitro activity of ciprofloxacin against gram-positive cocci. Am J Med. 1987 Apr 27;82(4A):27–32. [PubMed]
  • Bergan T, Thorsteinsson SB, Solberg R, Bjornskau L, Kolstad IM, Johnsen S. Pharmacokinetics of ciprofloxacin: intravenous and increasing oral doses. Am J Med. 1987 Apr 27;82(4A):97–102. [PubMed]
  • Campoli-Richards DM, Monk JP, Price A, Benfield P, Todd PA, Ward A. Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1988 Apr;35(4):373–447. [PubMed]
  • Koga H. High-performance liquid chromatography measurement of antimicrobial concentrations in polymorphonuclear leukocytes. Antimicrob Agents Chemother. 1987 Dec;31(12):1904–1908. [PMC free article] [PubMed]
  • Easmon CS, Crane JP. Uptake of ciprofloxacin by human neutrophils. J Antimicrob Chemother. 1985 Jul;16(1):67–73. [PubMed]
  • Rohwedder R, Bergan T, Thorsteinsson SB, Scholl H. Transintestinal elimination of ciprofloxacin. Chemotherapy. 1990;36(2):77–84. [PubMed]
  • Lebel M, Bergeron MG. Pharmacokinetics in the elderly. Studies on ciprofloxacin. Am J Med. 1987 Apr 27;82(4A):108–114. [PubMed]
  • Henry NK, Schultz HJ, Grubbs NC, Muller SM, Ilstrup DM, Wilson WR. Comparison of ciprofloxacin and co-trimoxazole in the treatment of uncomplicated urinary tract infection in women. J Antimicrob Chemother. 1986 Nov;18 (Suppl 500):103–106. [PubMed]
  • Tolkoff-Rubin NE, Rubin RH. Ciprofloxacin in management of urinary tract infection. Urology. 1988 Apr;31(4):359–367. [PubMed]
  • Newsom SW, Murphy P, Matthews J. A comparative study of ciprofloxacin and trimethoprim in the treatment of urinary tract infections in geriatric patients. J Antimicrob Chemother. 1986 Nov;18 (Suppl 500):111–115. [PubMed]
  • Haring JI, Van Dis ML. Odontogenic keratocysts: a clinical, radiographic, and histopathologic study. Oral Surg Oral Med Oral Pathol. 1988 Jul;66(1):145–153. [PubMed]
  • Guibert J, Destrée D, Konopka C, Acar J. Ciprofloxacin in the treatment of urinary tract infection due to enterobacteria. Eur J Clin Microbiol. 1986 Apr;5(2):247–248. [PubMed]
  • Weidner W, Schiefer HG, Dalhoff A. Treatment of chronic bacterial prostatitis with ciprofloxacin. Results of a one-year follow-up study. Am J Med. 1987 Apr 27;82(4A):280–283. [PubMed]
  • Ericsson CD, Johnson PC, Dupont HL, Morgan DR, Bitsura JA, de la Cabada FJ. Ciprofloxacin or trimethoprim-sulfamethoxazole as initial therapy for travelers' diarrhea. A placebo-controlled, randomized trial. Ann Intern Med. 1987 Feb;106(2):216–220. [PubMed]
  • DuPont HL, Ericsson CD, Robinson A, Johnson PC. Current problems in antimicrobial therapy for bacterial enteric infection. Am J Med. 1987 Apr 27;82(4A):324–328. [PubMed]
  • Ferreccio C, Morris JG, Jr, Valdivieso C, Prenzel I, Sotomayor V, Drusano GL, Levine MM. Efficacy of ciprofloxacin in the treatment of chronic typhoid carriers. J Infect Dis. 1988 Jun;157(6):1235–1239. [PubMed]
  • Lesse AJ, Freer C, Salata RA, Francis JB, Scheld WM. Oral ciprofloxacin therapy for gram-negative bacillary osteomyelitis. Am J Med. 1987 Apr 27;82(4A):247–253. [PubMed]
  • Gentry LO, Rodriguez GG. Oral ciprofloxacin compared with parenteral antibiotics in the treatment of osteomyelitis. Antimicrob Agents Chemother. 1990 Jan;34(1):40–43. [PMC free article] [PubMed]
  • Follath F, Bindschedler M, Wenk M, Frei R, Stalder H, Reber H. Use of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections. Eur J Clin Microbiol. 1986 Apr;5(2):236–240. [PubMed]
  • Fass RJ. Efficacy and safety of oral ciprofloxacin in the treatment of serious respiratory infections. Am J Med. 1987 Apr 27;82(4A):202–207. [PubMed]
  • Khan FA, Basir R. Sequential intravenous-oral administration of ciprofloxacin vs ceftazidime in serious bacterial respiratory tract infections. Chest. 1989 Sep;96(3):528–537. [PubMed]
  • Peterson PK, Stein D, Guay DR, Logan G, Obaid S, Gruninger R, Davies S, Breitenbucher R. Prospective study of lower respiratory tract infections in an extended-care nursing home program: potential role of oral ciprofloxacin. Am J Med. 1988 Aug;85(2):164–171. [PubMed]
  • Cooper B, Lawlor M. Pneumococcal bacteremia during ciprofloxacin therapy for pneumococcal pneumonia. Am J Med. 1989 Oct;87(4):475–475. [PubMed]
  • Righter J. Pneumococcal meningitis during intravenous ciprofloxacin therapy. Am J Med. 1990 May;88(5):548–548. [PubMed]
  • Edelstein PH. Legionnaires' disease. Clin Infect Dis. 1993 Jun;16(6):741–747. [PubMed]
  • Fong IW, Linton W, Simbul M, Thorup R, McLaughlin B, Rahm V, Quinn PA. Treatment of nongonococcal urethritis with ciprofloxacin. Am J Med. 1987 Apr 27;82(4A):311–316. [PubMed]
  • Naamara W, Plummer FA, Greenblatt RM, D'Costa LJ, Ndinya-Achola JO, Ronald AR. Treatment of chancroid with ciprofloxacin. A prospective, randomized clinical trial. Am J Med. 1987 Apr 27;82(4A):317–320. [PubMed]
  • Peterson LR, Lissack LM, Canter K, Fasching CE, Clabots C, Gerding DN. Therapy of lower extremity infections with ciprofloxacin in patients with diabetes mellitus, peripheral vascular disease, or both. Am J Med. 1989 Jun;86(6 Pt 2):801–808. [PubMed]
  • Gaunt PN, Lambert BE. Single dose ciprofloxacin for the eradication of pharyngeal carriage of Neisseria meningitidis. J Antimicrob Chemother. 1988 Apr;21(4):489–496. [PubMed]
  • Renkonen OV, Sivonen A, Visakorpi R. Effect of ciprofloxacin on carrier rate of Neisseria meningitidis in army recruits in Finland. Antimicrob Agents Chemother. 1987 Jun;31(6):962–963. [PMC free article] [PubMed]
  • Dekker AW, Rozenberg-Arska M, Verhoef J. Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin. Ann Intern Med. 1987 Jan;106(1):7–11. [PubMed]
  • Naber KG. Use of quinolones in urinary tract infections and prostatitis. Rev Infect Dis. 1989 Jul-Aug;11 (Suppl 5):S1321–S1337. [PubMed]
  • Alfaham M, Holt ME, Goodchild MC. Arthropathy in a patient with cystic fibrosis taking ciprofloxacin. Br Med J (Clin Res Ed) 1987 Sep 19;295(6600):699–699. [PMC free article] [PubMed]

Articles from CMAJ : Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association


BUY NOW For Sale 70%!
buy viagra

Antibiotics for Ear Infections in Adults M Cipro tendonitis symptoms

Linola akut beipackzettel ciprofloxacin Management of Inflammatory Bowel Disease
Linola akut beipackzettel ciprofloxacin Un buon albergo, Cipro Nord per escursioni. - Recensioni su Salamis
Linola akut beipackzettel ciprofloxacin Full text of Atti e memorie della Societ tiburtina di storia e d arte
Linola akut beipackzettel ciprofloxacin Cathter chambre implantable - Verrou de TT Vancomycine
Linola akut beipackzettel ciprofloxacin CIPRO XR ( Cloridrato de Ciprofloxacina) BulasMed
Linola akut beipackzettel ciprofloxacin Doxycycline Dosage - eMedTV: Health Information
Linola akut beipackzettel ciprofloxacin The Classic Hotel a Nicosia da 76 - Trabber Hotel
Linola akut beipackzettel ciprofloxacin Augmentin - What s up with that? - Ulcerative Colitis
Linola akut beipackzettel ciprofloxacin Cyclizine oral and methadone oral Drug Interactions - RxList
MCSA Montpellier Culture Sport Adapt - Le MCSA C Difficile Infection and Antibiotic Colitis are Serious Urinary Tract Infection - Adults Treatment - The New York Times Cipro 5 oral - Cipro and birth control webmd - Allergic reaction Drugs Online Without a Prescription Cannoleria - Pasticcerie di Roma The Powerhouse Group
BUY NOW For Sale 70%!
buy viagra